Last close As at 07/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Research: Healthcare
Scandion Oncology has announced the appointment of Francois Martelet, MD, as CEO, effective from 2 January 2023, when he will take over from acting CEO and CFO Johnny Stilou. Francois brings more than 30 years of pharmaceutical industry experience to Scandion, and will lead the development of Scandion’s chemotherapy sensitising drug SCO-101 in colorectal and pancreatic cancer. Previously, Francois held a number of biotech CEO positions and has extensive leadership experience at large pharmaceutical companies. We see his appointment as a positive step for the company following the departure of Bo Rode Hansen from the top position in August 2022. The appointment comes ahead of a year that will include a number of important catalysts from Scandion’s development pipeline.
Written by
Scandion Oncology |
Francois Martelet appointed as CEO |
Management change |
Pharma and biotech |
1 December 2022 |
Share price performance
Business description
Analysts
Scandion Oncology is a research client of Edison Investment Research Limited |
||||||||||||||||||||||||||||||||||||
Scandion Oncology has announced the appointment of Francois Martelet, MD, as CEO, effective from 2 January 2023, when he will take over from acting CEO and CFO Johnny Stilou. Francois brings more than 30 years of pharmaceutical industry experience to Scandion, and will lead the development of Scandion’s chemotherapy sensitising drug SCO-101 in colorectal and pancreatic cancer. Previously, Francois held a number of biotech CEO positions and has extensive leadership experience at large pharmaceutical companies. We see his appointment as a positive step for the company following the departure of Bo Rode Hansen from the top position in August 2022. The appointment comes ahead of a year that will include a number of important catalysts from Scandion’s development pipeline.
Year end |
Revenue (DKKm) |
PBT* (DKKm) |
EPS* |
DPS |
DPS |
Yield |
12/19 |
1.0 |
(21.5) |
(0.53) |
0.0 |
N/A |
N/A |
12/20 |
0.8 |
(57.2) |
(1.61) |
0.0 |
N/A |
N/A |
12/21e |
0.6 |
(87.7) |
(2.25) |
0.0 |
N/A |
N/A |
12/22e |
0.6 |
(75.8) |
(1.73) |
0.0 |
N/A |
N/A |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Investor attention remains focused on the development programme for SCO-101, a chemosensitiser that Scandion believes can reverse chemotherapy resistance. Francois will oversee a number of important catalysts for Scandion in FY23. Following top-line data from CORIST part 2, Scandion is enrolling patients for CORIST part 3, which is investigating use of the SCO-101/FOLFIRI combination in both mutant and wild-type RAS metastatic colorectal cancer (mCRC) patients. The company expects a new dosing regimen in part 3 could be more efficacious than previous regimens and top-line results are expected in Q323. CORIST part 4, which we expect could begin as soon as Q323 (subject to part 3 enrolment), will then assess the efficacy of the optimised SCO-101/FOLFIRI dosing protocol (n=24) identified in part 3. Management will provide an update on clinical timelines in Q123.
In addition, data from the Phase Ib PANTAX study in pancreatic cancer is expected in H123. If the SCO-101/gemcitabine/paclitaxel combination being studied can show signs of efficacy here, we expect this will increase confidence in management’s development plans in mCRC. The trial will primarily assess the safety and tolerability of the SCO-101/gemcitabine/paclitaxel combination; however, secondary endpoints, including objective response rate, progression free survival, overall survival and pharmacokinetic profile, will be a crucial focus, in our view, following the CORIST part 2 data.
|
|
Research: Consumer
Britvic reported strong double-digit revenue growth across all business units in FY22, reflecting brand resilience despite significant headwinds. Trading benefited from a full year with no COVID-19-related restrictions and hot weather during the summer. Performance was boosted by balanced growth in volume and price, as management mitigated the significant cost inflation in the year through price rises and efficiency initiatives. As such, adjusted EBIT was up 17% while adjusted EPS grew 29.3%. The dividend per share increased 19.8% to 29p. Despite the more challenging macroeconomic environment, management notes no slowdown in consumer demand, with current trading in line with expectations. Although current headwinds on costs and consumer spend are expected to persist into FY23, management believes it is well positioned to navigate these challenges successfully.